FDA Maintained Hold on Newron Alzheimer’s Study
The agency continues to pause U.S. enrollment for the ENIGMA-TRS 2 trial following an unexpected participant death.
Updated on Sept. 25, 2026 in Alzheimer’s
Live Poll
Do you trust pharmaceutical companies to maintain rigorous safety standards during the drug development process?
The FDA has kept a clinical hold in place on new patient enrollment for Newron’s ENIGMA-TRS 2 study in the United States. While the trial continues in other regions, no U.S. patients have yet been dosed with the study treatment, evenamide.
Why it matters
The clinical hold remains active as the FDA evaluates additional information regarding the study protocol to ensure safety standards. This development impacts the timeline for U.S.-based research into new treatment options for those managing Alzheimer’s disease.
An independent international safety monitoring board reviewed data following the unexpected death of a study participant at a non-U.S. clinical site. The board recommended that the studies continue as designed, despite the ongoing FDA hold on new U.S. enrollment.
The players
FDA
The federal agency responsible for overseeing the safety and efficacy of clinical trials and medical treatments in the United States.
Newron
A pharmaceutical company headquartered in Milan, Italy, focused on developing novel therapies for central nervous system disorders.
The details
The ENIGMA-TRS 2 study tests evenamide as a potential treatment for Alzheimer's, with participants evaluated for clinical response at doses of 15mg or 30mg. The FDA instituted the hold on April 29, 2026, after Newron reported an unexpected participant death at an international site. While the local investigator determined the event was unrelated to the study drug, the agency is requiring further review of the study protocols.
Timeline
April 29, 2026: The FDA initiated a clinical hold on U.S. enrollment.
September 25, 2026: Newron confirmed the FDA hold remains in place.
Q1 2027: Newron expects to report results from the ENIGMA-TRS 1 assessment.
Health Landscape
This development occurs within the context of the global ENIGMA-TRS research program investigating evenamide for Alzheimer’s disease. The FDA’s regulatory oversight marks a departure from the progress seen in the study's international sites, where enrollment remains active.
If you are participating in or considering clinical trials for Alzheimer's, discuss the implications of safety protocols with your medical team. Clinical holds are standard regulatory safeguards used to protect participant welfare when unexpected events occur during drug trials.
The takeaway
Clinical trial holds, while concerning, are built-in safety mechanisms intended to ensure rigorous oversight of research protocols. Patients interested in trial participation should speak with their physician to understand how regulatory actions like these may affect study timelines.
Further reading
For broader context on research developments, visit the Alzheimer’s section.
Live Poll
Do you trust pharmaceutical companies to maintain rigorous safety standards during the drug development process?
